Many anticancer drugs regulate DUSP1 expression and immune invasion in TME; for example, sorafenib, a common drug used for HCC treatment, apart from multi-kinase inhibition, sorafenib exposure in HCC modulates anti-tumor effect via macrophages. This evidence concerns the gene DUSP1 and hepatocellular carcinoma.